Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR Path 1 pediatric bempedoic acid study in HeFH
2024-515864-30-00Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of bempedoic acid in heterozygous familial hypercholesterolemia (HeFH), sponsored by Esperion Therapeutics. Primary endpoints: Observed trough plasma concentration of ETC-1002 after 8 weeks and Model-based pharmacokinetic parameters of ETC-1002. Started Sep 2024; status: completed.
02
Drugs
bempedoic acid
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2024-515864-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515864-30-00.